Last reviewed · How we verify
Lenalidomide and Azacitidine for Adaptive Immunotherapy in Multiple Myeloma: Pilot Study of Autologous Lymphocyte Mobilization Following Immuno-modulatory Therapy
RATIONALE: Lenalidomide may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. An autologous stem cell transplant may be able to replace blood-forming cells that were destroyed by lenalidomide and azacitidine. Giving autologous lymphocytes after the transplant may help destroy any remaining cancer cells. PURPOSE: This pilot trial is studying how well giving lenalidomide together with azacitidine works when followed by autologous stem cell transplant and autologous lymphocyte infusion in treating patients with multiple myeloma.
Details
| Lead sponsor | Virginia Commonwealth University |
|---|---|
| Phase | NA |
| Status | COMPLETED |
| Enrolment | 17 |
| Start date | 2010-01 |
| Completion | 2016-09 |
Conditions
- Multiple Myeloma
Interventions
- Azacitidine
Primary outcomes
- Feasibility to Mobilize and Infuse Autologous Lymphocytes (ALI) After Immunomodulatory Therapy and After Stem Cell Transplant Engraftment — 6 months
Time frame is post 2nd and 3rd cycles of rev/aza and after stem cell transplant engraftment.
Countries
United States